Documents A 1 Risk Management Program

1. Risk Management Program for Lotronex ® (alosetron hydrochloride) Tablets Craig A. Metz, PhD VP, US Regulatory Affairs GlaxoSmithKline 2. Consultants Robert Sandler, MD,…

Documents 1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director,...

Slide 1 1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products April…

Documents COMORBIDITIES IN PATIENTS WITH IRRITABLE BOWEL SYNDROME Natalia Pritcan Alina Burianov,Gheata Irina....

COMORBIDITIES IN PATIENTS WITH IRRITABLE BOWEL SYNDROME Natalia Pritcan Alina Burianov,Gheata Irina Doctor Melania Macarie Faculty of Medicine, UMPh Targu Mureş Department…

Documents Untitled

Qualitative Development of a Patient-Reported Outcome Symptom Measure in Diarrhea-Predominant Irritable Bowel Syndrome P. Marquis, MD, MBA1,9, K.E. Lasch, PhD, MA, MSSW2,9,…